Compare SVM & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | CGEM |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.4B |
| IPO Year | 2005 | 2020 |
| Metric | SVM | CGEM |
|---|---|---|
| Price | $11.52 | $20.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $10.50 | ★ $30.13 |
| AVG Volume (30 Days) | ★ 2.1M | 701.9K |
| Earning Date | 05-25-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.87 | N/A |
| Revenue Next Year | $35.34 | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.00 | $5.68 |
| 52 Week High | $15.77 | $23.19 |
| Indicator | SVM | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 43.84 |
| Support Level | $9.66 | $11.87 |
| Resistance Level | $11.48 | $23.19 |
| Average True Range (ATR) | 0.57 | 0.92 |
| MACD | -0.22 | -0.38 |
| Stochastic Oscillator | 0.61 | 30.77 |
Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.